Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$319.36 USD

319.36
572,370

-12.77 (-3.85%)

Updated Sep 17, 2025 01:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

by Zacks Equity Research

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.

Zacks Equity Research

Thermo Fisher (TMO) Launches New Solutions for Clinical Labs

by Zacks Equity Research

Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.

Zacks Equity Research

Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook

by Zacks Equity Research

Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.

Zacks Equity Research

Illumina (ILMN) Expands Globally Despite Macroeconomic Woes

by Zacks Equity Research

The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.

Zacks Equity Research

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Zacks Equity Research

If You Invested $1000 in Insulet a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY

by Zacks Equity Research

Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.

Zacks Equity Research

Centene's (CNC) Ambetter Enhances Offerings With Broward Health

by Zacks Equity Research

Centene's (CNC) Health Insurance Marketplace brand Ambetter strengthens its provider network with Broward Health.

Zacks Equity Research

BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS

by Zacks Equity Research

BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.

Zacks Equity Research

Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden

by Zacks Equity Research

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.

Zacks Equity Research

Centene (CNC), Mindoula to Address Mental Health Issues in Indiana

by Zacks Equity Research

Centene's (CNC) unit, MHS, collaborates with Mindoula to enhance mental health support for Hoosiers and attract more customers to opt for CNC's Medicaid plans.

Zacks Equity Research

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing

by Zacks Equity Research

OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.

Zacks Equity Research

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Zacks Equity Research

Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail

by Zacks Equity Research

Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Zacks Equity Research

Neogen (NEOG) to Offer Biosecurity Products With New Pact

by Zacks Equity Research

Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.

Zacks Equity Research

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.

Zacks Equity Research

Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC

by Zacks Equity Research

Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.

Zacks Equity Research

Integra Gains From New Product Launches, Mounting Costs Ail

by Zacks Equity Research

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Zacks Equity Research

Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Zacks Equity Research

Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal

by Zacks Equity Research

Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.